Why the study?
Preclinical identification of Duchenne muscular dystrophy therapeutics has been hampered by the lack of a small animal model that recapitulates human disease features.
Does the D2.mdx mouse model better recapitulate the skeletal muscle pathology of Duchenne muscular dystrophy compared to the B10.mdx model?
Population
D2.mdx mice
Comparison
D2.mdx model vs B10.mdx model
Design
Preclinical animal model study
Authors
Loading...
D2.mdx may better model severe DMD pathology in preclinical studies; leaves open translation to human trials.
Does the D2.mdx mouse model better recapitulate the skeletal muscle pathology of Duchenne muscular dystrophy compared to the B10.mdx model?
The D2.mdx mouse model demonstrates severe histopathological features and functional decline, establishing it as a superior preclinical model for Duchenne muscular dystrophy compared to the traditional B10.mdx model.
Hammers et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: